AZNAstraZeneca PLC
Is it safe?
Nothing alarming, nothing pristine: insiders buying, comfortable debt (A), and typical volatility.
Insiders were net buyers (+$3K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -28% · now 24% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AZN take a bad year?
The deepest fall in AZN's price history on file is −28%; it is 24% below its high today.
Net debt · as at Q2 2025 · debt less the cash on hand
- Interest cover
- 7.95×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 26%
Annualised volatility · about as steady as the market itself
- Worst drawdown on file
- −28%
Worst drawdown on file · −24% today
Details›
- Total debtQ2 2025
- $35.7B
- Cash and short-term investments
- $7.06B
- Net debt
- $28.6B
- Operating profit, trailing twelve months
- $13.0B
- Debt / equity
- 0.80×
- Annualised volatilitytwo years of daily moves
- 26%
- Worst drawdown on file
- −28%
- Below its 52-week high
- 24%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
Ranks #5 of 7 by RyuScore